PD-1 inhibition in bone sarcoma and soft-tissue sarcoma
Mené sur 84 patients atteints d'un sarcome osseux ou d'un sarcome des tissus mous de stade avancé, cet essai multicentrique de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité du pembrolizumab, après l'échec de 1 à 3 lignes de traitement systémique
Sarcoma is a highly heterogeneous malignancy (>50 histological subtypes), for which active treatments beyond doxorubicin and ifosfamide are restricted to only some histological subtypes.1 Therefore, treatment selection in advanced disease is mainly based on histological subtype, although this approach has limitations in the perioperative setting.2
The Lancet Oncology , commentaire, 2016